Japan

Population 2017: 127 million

Tuberculosis profile

**Estimates of TB burden**, 2017

<table>
<thead>
<tr>
<th></th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>2.8 (2.7–2.9)</td>
<td>2.2 (2.1–2.3)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.013 (&lt;0.01–0.019)</td>
<td>0.01 (0.01–0.01)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>19 (17–22)</td>
<td>15 (13–17)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>0.085 (0.07–0.1)</td>
<td>0.07 (0.05–0.08)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>0.57 (0.24–1.1)</td>
<td>0.45 (0.18–0.83)</td>
</tr>
</tbody>
</table>

**Estimated TB incidence by age and sex (thousands)**, 2017

<table>
<thead>
<tr>
<th>Age group</th>
<th>Females</th>
<th>Males</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-4 years</td>
<td>0.79 (0.77–0.81)</td>
<td>1 (0.97–1)</td>
<td>1.8 (1.7–1.9)</td>
</tr>
<tr>
<td>&gt; 14 years</td>
<td>6.9 (6.3–7.5)</td>
<td>11 (9.4–12)</td>
<td>18 (15–20)</td>
</tr>
</tbody>
</table>

**TB case notifications**, 2017

- Total cases notified: 16,789
- Total new and relapse cases: 16,789
- % with known HIV status: 9%
- % with known pulmonary TB cases: 77%
- % bacteriologically confirmed among pulmonary: 86%

**Universal health coverage and social protection**

- TB treatment coverage (notified/estimated incidence), 2017: 87% (75–100)
- TB/HIV care in new and relapse TB patients, 2017: Patients with known HIV-status who are HIV-positive: 34% (2%)
- on antiretroviral therapy

**Drug-resistant TB care**, 2017

- Estimated MDR/RR-TB cases among notified cases: 360 (140–590)
- Estimated % of TB cases with MDR/RR-TB: 2.3% (0.86–4.4) / 12% (7.2–19)
- % notified tested for rifampicin resistance: 52% / 46% 8,856
- MDR/RR-TB cases tested for resistance to second-line drugs

**Laboratory-confirmed cases**

- MDR/RR-TB: 86, XDR-TB: 8

**Treatment success rate and cohort size**

- New and relapse cases registered in 2016: 70% (17,539)
- Previously treated cases, excluding relapse, registered in 2016: 57% (44)
- MDR/RR-TB cases started on second-line treatment in 2015: 86
- XDR-TB cases started on second-line treatment in 2015: 8

**TB preventive treatment**, 2017

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 55% (41–86)
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 55% (41–86)

**TB financing**, 2018

- National TB budget (US$ millions): 43

*Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2018-09-28  Data: www.who.int/tb/data